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Aims To characterize patient radiation doses from nuclear myocardial perfusion imaging (MPI) and the use of radiation-
optimizing ‘best practices’ worldwide, and to evaluate the relationship between laboratory use of best practices and
patient radiation dose.
Methods
and results
Weconducted anobservational cross-sectional studyof protocols used forall 7911MPI studies performed in 308nuclear
cardiology laboratories in 65 countries for a single week in March–April 2013. Eight ‘best practices’ relating to radiation
exposurewere identified a priori by an expert committee, and a radiation-related quality index (QI) devised indicating the
number of best practices used by a laboratory. Patient radiation effective dose (ED) ranged between 0.8 and 35.6 mSv
(median 10.0 mSv). Average laboratory ED ranged from 2.2 to 24.4 mSv (median 10.4 mSv); only 91 (30%) laboratories
achieved the median ED ≤ 9 mSv recommended by guidelines. Laboratory QIs ranged from 2 to 8 (median 5). Both ED
and QI differed significantly between laboratories, countries, and world regions. The lowest median ED (8.0 mSv), in
Europe, coincided with high best-practice adherence (mean laboratory QI 6.2). The highest doses (median 12.1 mSv)
and low QI (4.9) occurred in Latin America. In hierarchical regression modelling, patients undergoing MPI at laboratories
following more ‘best practices’ had lower EDs.
* Corresponding author. Tel: +1 212 305 6812, Fax:+1 212 305 4648, Email: andrew.einstein@columbia.edu
& The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
European Heart Journal (2015) 36, 1689–1696
doi:10.1093/eurheartj/ehv117
Conclusion Marked worldwide variation exists in radiation safety practices pertaining to MPI, with targeted EDs currently achieved in
a minority of laboratories. The significant relationship between best-practice implementation and lower doses indicates
numerous opportunities to reduce radiation exposure from MPI globally.
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Introduction
Nuclear myocardial perfusion imaging (MPI) is a non-invasive diag-
nostic test widely used to diagnose coronary artery disease,1 stratify
risk,2 predict outcomes,3 guide patient management,4 and control
costs.5 Reflecting these benefits, MPI volume has grown rapidly
worldwide over the past two decades, to 15–20 million procedures
annually6 and diffusion of technology and expertise has led to its con-
tinued adoption across the developing world. However, significant
concerns have been raised over radiation-related cancer risk from
cardiac imaging7 – 10 and, in particular, the radiation burden from
MPI. While considerable worldwide variation exists in the frequency
of MPI use,11 in some settings, such as the USA, it is the medical test
with the highest per capita radiation dose.9,12,13 Estimation of risk
from ionizing radiation is difficult, since no prospective trials focusing
on adverse events of radiation with doses used in diagnostic proce-
dures have ever been performed.28 A variety of protocols can be
used to perform MPI14,15 on single-photon emission computed tom-
ography (SPECT) and positron emission tomography (PET) cameras,
and a variety of approaches and ‘best practices’ have been developed
to lower radiation exposures to patients. While preliminary single-
country data suggest that radiation safety technique is frequently sub-
optimal,16 the worldwide use of strategies that may reduce dose has
never been characterized. A better understanding of current practice
would offer opportunities to identify areas to improve quality of care
and to reduce disparities, which in turn would decrease the global ra-
diation burden from MPI. Thus, we undertook to characterize world-
wide nuclearcardiologypractice and its impact on radiationexposure
to patients and populations, including variation in radiation doses and
the use of ‘best practices’ and dose-lowering techniques.
Methods
Study design and survey conduct
A needs assessment expert meeting was organized by the International
Atomic Energy Agency (IAEA) in 2012 and identified knowledge of
worldwide MPIprotocols andpractices as an important priority. Wecon-
ducted a cross-sectional study in centres performing MPI. We obtained
contact details of nuclear cardiology laboratories and practitioners
from databases provided by national and international organizations
(see Supplementary material online, Methods), and from designated
INCAPS regional coordinators. On 15 March 2013, the IAEA contacted
potential sites and requested that they participate voluntarily in a study
aimed at identifying what laboratories ‘around the world [are] doing in
terms of tracer utilization, doses used and technology that is available’
based on a consecutive series of patients over 1 week, chosen by the re-
spondent, between the weeks beginning 19 March and 22 April, inclusive.
The study was approved by the Columbia University Institutional Review
Board, which declared it exempt from the requirements of US federal
regulations for the protection of human subjects (45 CFR 46) since the
study collected no individually identifiable health information.
Data collection instrument
A standardized data collection instrument was emailed to all potential
participants. A local investigator at each site provided information on
laboratory demographics, as well as patient demographics and clinical
characteristics for each MPI study completed during the selected week,
including the patient’s age, gender, and weight, radiopharmaceuticals
used and injected activities, camera type, patient positioning, additional
scanning (CT or nuclear) performed for attenuation correction, and
hardware and software used that improves camera efficiency. Data
were checked for omissions and errors, and sites contacted when clari-
fication was required; all sites responded and successfully addressed
these concerns.
Radiation dose estimation
Radiation exposure was quantified by the effective dose (ED), a whole-
body measure reflecting the dose to each organ and its relative sensitivity
to the deleterious effects of radiation. ED was calculated for each patient
based on the radiopharmaceutical(s) administered and their activities
(MBq), using the most recent dosimetry as specified by the International
Commission on Radiological Protection.17,18 For rubidium-82, ED was
calculated according to the approach of Senthamizhchelvan.19 Achieve-
ment of median ED ≤9 mSv, a target established in professional
society recommendations,20 was evaluated for each laboratory.
Best practices quality index
Acquired data were used to determine each laboratory’s adherence to
eight ‘best practices’ with bearing on radiation exposure, based on
current clinical practice guidelines.14,15,21 These criteria (Table 1) were
determined, prior to data analysis, by a committee of expert physicians
and medical physicists convened by IAEA, charged with identifying the
critical, measurable practices that impact and optimize radiation dose
from MPI. The core elements identified by the panel included practices
such as avoiding administering too much isotope, avoiding higher dose
isotopes (viz. thallium-201), and using newer technologies that can
lower radiation doses.
The panel also a priori devised a best practices quality index (QI),
defined as the number (0–8) of best practices adhered to by a laboratory
during the specified week; a QI score of ≥6 was pre-specified by the
panel, prior to data analysis, as a desirable level.
Statistical methods
We calculated radiation dose (ED) for each patient and QI score for each
laboratory as above. Continuous variables were described in terms of
means (+standard deviation) and medians (interquartile range; IQR),
and compared using analysis of variance and Kruskal–Wallis tests, re-
spectively. Categorical variables were compared using x2 tests. Compar-
isons were performed at the world regional level. World regions were
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defined as Africa, Asia, Europe, Latin America (including Mexico, Central
and South America), North America (Canada and United States), and
Oceania (Australia and New Zealand).
Hierarchical linear regression models were developed to determine if
laboratory adherence to best practices was associated with patient ED,
adjusting for patient clustering by laboratory and country. Model regres-
sion coefficients correspond to the expected change in ED associated
with adherence to a specific best practice. The eight best practices
were included as independent variables (fixed factors), and treated as di-
chotomous (laboratory adherence: yes/no). The intercept wasdefined as
a random factor. The dependent variable was patient ED (mSv). We per-
formed analyses with and without adjustment for patient age, gender, and
weight. Additional linear regression models were developed to evaluate
the impact of laboratory characteristics on QI. Independent variables
included laboratory procedure volume (continuous variable), world
region (categorical with Europe as reference category), and the labora-
tory’s country’s World Bank income level22 (low/low-middle (reference)
vs. high-middle vs. high). Correlations between model variables were
assessed using Pearson’sw. A two-tailed P, 0.05 was considered signifi-
cant for all statistical tests. All analyses were performed using Stata/SE
13.1 (StataCorp, College Station, TX, USA).
Results
Data were collected on all 7911 patients undergoing MPI in 308 la-
boratories in 65 countries, during the specified 1-week period.
Mean patient age was 64.1+12.0 years, and 41% were female.
Mean ED for all patients was 10.0+ 4.5 mSv. The distribution of
patient ED showed a slight positive skew, with 978 patients (12%) re-
ceiving an estimated ED of .15 mSv (Figure 1). Both mean and
median ED differed between laboratories (see Supplementary ma-
terial online, Table S1), countries (see Supplementary material
online, Table S2), and world regions (P, 0.001 for each). World-
wide, only 30% of laboratories had median ED ≤9 mSv. Adherence
to best practices (Table 2) varied markedly between laboratories
(mean QI score 5.4+ 1.3), countries (see Supplementary material
online, Table S2), and world regions (Table 3). Only 46% of laborator-
ies adhered to six or more best practices.
Regional variation
The burden of radiation to patients undergoing MPI differed
between world regions (Figure 1). Europe had both the lowest
mean (7.9 mSv) and median (8.0 mSv) ED, and the highest propor-
tion of patients with ED ≤9 mSv (60%). Latin America and Asia had
the highest doses (mean of 11.8 and 11.4 mSv, respectively) and the
second lowest proportion of patients with ED ≤9 mSv (27% and
24%, respectively). Europe was also among the highest in adherence
to best practices with a mean laboratory QI of 6.2;71% of labora-
tories adhered to six or more best practices (Table 3). North
America had the lowest mean laboratory QI score (4.7), and was
among the lowest in proportion of laboratories with ≥6 best prac-
tices (31%).
Table 1 Definitions of the eight best practices
1. Avoid thallium stress: No thallium stress tests were performed in patients ≤70 years old. SPECT MPI performed with thallium-201 is associated with a
considerably higher radiation dose to patients than when it is performed with technetium-99m.29 This excludes thallium rest-redistribution viability studies
and stress-redistribution-reinjection stress-and-viability studies.
2. Avoid dual isotope: No dual isotope (rest thallium and stress technetium) stress tests were performed in patients ≤70 years old. Dual isotope MPI is
associated with the highest radiation dose of any protocol.29
3. Avoid too much technetium: No study was performed with administered activity.1332 MBq (36 mCi) for an injection of technetium, and mean total
effective dose was,15 mSv for all studies using just technetium injections. 1332 MBq is the highest recommended activity in guidelines,15 and 15 mSv is a
high radiation dose for a study using technetium-99m.
4. Avoid too much thallium: For each nuclear stress test involving thallium, no more than 129.5 MBq (3.5 mCi) was administered at stress. The expert
committee maintained that no more than this activity is needed for patients who are good candidates to receive thallium MPI.
5. Perform stress-only imaging: The laboratory performed at least one stress-only study, in which rest imaging was omitted, or the laboratory only does
PET-based stress tests. If stress images are completely normal, subsequent rest imaging can be avoided to reduce radiation dose by up 80%. PET MPI studies
have low radiation dose, the dosimetric advantage of stress-only is less, and there is less evidence regarding stress-only PET MPI.
6. Use camera-based dose-reduction strategies: The laboratory performed at least one study using at least one of the following: (i) attenuation
correction (CT or line source), (ii) imaging patients in multiple positions, e.g. both supine and prone, (iii) high-technology software (e.g. incorporating
iterative reconstruction, resolution recovery, andnoise reduction), and (iv) high-technologyhardware (e.g. PET, ahigh-efficiency solid-stateSPECTcamera,
or a cardiac-focused collimator). Each of these approaches reduces the radiation dose needed or facilitates performance of stress-only imaging.
7. Weight-based dosing for technetium: The laboratory had a statistically significant positive correlation between patient weight and administered
activity (MBq), for injections of technetium. Tailoring the administered activity to the patient size offers an opportunity to reduce radiation dose.
8. Avoid inappropriate dosing that can lead to ‘shine through’ artefact: The laboratory performed no SPECT MPI studies with technetium rest and
stress injections on the same day, in which activity of the second injection was ,3× that of the first injection. Shine through occurs in two injection,
single-day technetium studies when residual radioactivity from the first injection interferes with interpretation of images for the second injection. To avoid
shine through, it is recommended in guidelines that the activity (mCi or MBq) imaged for the second injection be at least three to four times that of the first
injection; in some cases, this can be achieved with a second injection that has less than four times the activity by waiting for some of the technetium-99 m to
decay. Reflecting guidelines, we considered a second injection of less than three times the activity of the first injection to constitute dosing that can lead to
shine through.14,15,21,30
A committee of international experts convened at the IAEA, including physicians and medical physicists, developed these criteria to be applied to nuclear cardiology laboratories.
SPECT, single-photon emission computed tomography; MPI, myocardial perfusion imaging; MBq, megabecquerel; mCi, millicurie; PET, positron emission tomography; CT, computed
tomography.
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Laboratory radiation burden and
adherence to best practices
Based on the regression analysis, undergoing a procedure at a labora-
tory that adhered to each of the best practices was associated with
significantly lower patient ED. The only exceptions were laboratory
adherence to avoiding ‘too much thallium’ and avoiding inappropriate
dosing that can lead to ‘shine through’ (i.e. best practices 4 and 8 in
Table 1, respectively). This relationship was maintained even after
adjustment for patient age, gender, and weight. Laboratory avoidance
of dual isotope use in patients under 70 years old was associated with
Figure 1 Worldwide distribution of patient radiation effective doses from myocardial perfusion imaging. Inset displays the distribution of patient
effective doses by region.
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Table 2 Best practice adherence by region
Number (%) of laboratories adhering to best practice
Africa Asia Europe Latin America North America Oceania Total P-Value
Laboratories 12 69 102 36 55 34 308 n/a
Best practices
Avoid thallium stress 12 (100) 52 (75) 97 (95) 35 (97) 55 (100) 31 (91) 282 (92) ,0.001
Avoid dual isotope 12 (100) 64 (93) 101 (99) 34 (94) 53 (96) 34 (100) 298 (97) 0.2
Avoid too much technetium 11 (92) 64 (93) 101 (99) 23 (64) 33 (60) 31 (91) 263 (85) ,0.001
Avoid too much thallium 12 (100) 68 (99) 102 (100) 35 (97) 55 (100) 34 (100) 306 (99) 0.48
Perform stress-only imaging 8 (67) 16 (23) 47 (46) 7 (19) 9 (16) 6 (18) 93 (30) ,0.001
Use camera-based dose-reduction strategies 8 (67) 48 (70) 71 (70) 16 (44) 33 (60) 30 (88) 206 (67) 0.005
Weight-based dosing for technetium 6 (50) 8 (12) 48 (47) 11 (31) 10 (18) 5 (15) 88 (29) ,0.001
Avoid ‘shine through’ 7 (58) 26 (38) 66 (65) 14 (39) 8 (15) 15 (44) 136 (44) ,0.001
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Table 3 Demographics, radiation burden, and adherence to best practices by world region
Africa Asia Europe Latin America North America Oceania Total P-Value
Countries 6 18 27 10 2 2 65 n/a
Laboratories 12 69 102 36 55 34 308 n/a
Patients/lab, mean (SD) 29.0 (23.7) 21.3 (23.9) 23.3 (32.8) 31.6 (37.7) 38.9 (38.8) 12.9 (9.8) 25.7 (31.6) 0.002
Patients/lab, median (IQR) 19 (10–48) 15 (6–29) 15 (8–28) 12 (8–42) 31 (14–46) 9.5 (6–17) 16 (8–33) ,0.001
Average ED (mSv), mean (SD) 9.3 (3.9) 11.7 (4.1) 8.7 (3.1) 13.0 (2.8) 12.0 (3.6) 10.3 (2.4) 10.7 (3.7) ,0.001
Average ED (mSv), median 9.4 11.4 8.8 12.8 12.1 11.4 10.9 ,0.001
Average ED (mSv), IQR 6.3–13.6 9.7–13.0 6.3–10.8 11.3–14.9 9.5–13.3 9.4–11.7 8.4–12.9 n/a
Average ED (mSv), range 3.5–15.2 2.2–21.5 3.1–18.0 7.8–18.6 3.7–24.4 3.1–14.3 2.2–24.4 n/a
Number with median ED ≤9 mSv 5 (42%) 12 (17%) 52 (51%) 4 (11%) 11 (20%) 7 (21%) 91 (30%) ,0.001
QI score, mean (SD) 6.3 (1.2) 5.0 (1.1) 6.2 (1.2) 4.9 (1.0) 4.7 (1.2) 5.5 (0.7) 5.4 (1.3) 0.02
QI score, median (IQR) 6.5 (5.5–7) 5 (4–6) 6 (5–7) 5 (4–5) 5 (4–6) 6 (5–6) 5 (5–6) ,0.001
QI score
2 0 0 0 1 (3%) 1 (2%) 0 2 (1%)
3 0 4 (6%) 0 0 11 (20%) 0 15 (5%)
4 1 (8%) 18 (26%) 10 (10%) 12 (33%) 12 (22%) 3 (9%) 56 (18%)
5 2 (17%) 29 (42%) 20 (20%) 15 (42%) 14 (25%) 13 (38%) 93 (30%)
6 3 (25%) 12 (17%) 28 (27%) 6 (17%) 16 (29%) 17 (50%) 82 (27%)
7 4 (33%) 3 (4%) 27 (26%) 2 (5%) 1 (2%) 1 (3%) 38 (12%)
8 2 (17%) 3 (4%) 17 (17%) 0 0 0 22 (7%)
Number with ≥6 best practices 9 (75%) 18 (25%) 72 (71%) 8 (22%) 17 (31%) 18 (53%) 142 (46%) ,0.001
Patients 348 1469 2381 1139 2135 439 7911 n/a
Female 135 (39%) 559 (38%) 949 (40%) 492 (43%) 921 (43%) 198 (45%) 3254 (41%) 0.005
Age, mean (SD) 60.2 (11.0) 61.8 (12.5) 65.3 (11.1) 62.4 (11.5) 65.8 (12.3) 65.4 (12.6) 64.1 (12.0) ,0.001
Weight (kg), mean (SD) 81.2 (15.8) 71.6 (15.7) 80.0 (16.7) 77.8 (16.0) 87.2 (21.5) 83.0 (20.1) 80.2 (18.7) ,0.001
ED (mSv), mean (SD) 9.7 (5.5) 11.4 (4.8) 7.9 (3.5) 11.8 (4.1) 10.5 (4.5) 9.3 (3.7) 10.0 (4.5) ,0.001
ED (mSv), median 9.1 11.4 8.0 12.1 11.4 10.1 10.2 ,0.001
ED (mSv), IQR 5.1–15.6 9.2–13.5 5.1–10.1 8.4–14.6 8.0–12.9 6.5–11.7 6.7–12.7 n/a
ED (mSv), range 1.8–20.0 1.0–35.6 0.8–25.9 2.2–27.1 0.9–28.1 0.9–17.9 0.8–35.6 n/a
Number with ED ≤9 mSv 173 (50%) 358 (24%) 1420 (60%) 304 (27%) 649 (30%) 161 (37%) 3065 (39%) ,0.001
Stress-only tests 109 (31%) 272 (19%) 461 (19%) 54 (4.7%) 54 (2.5%) 55 (13%) 1005 (13%) ,0.001
Quality index (QI) is the number of best practices adhered to by a laboratory. Mean and median QI values are based on laboratory scores in each region. Effective dose (ED) mean and median estimates are based on patient estimates in each region.
NC, nuclear cardiology; SD, standard deviation; IQR, interquartile range.
IA
EA
N
uclear
C
ardiology
Protocols
Study
1693
the largest reduction in ED (5.4 mSv). The results of the hierarchical
regression model adjusted for age, gender, and weight are presented
in Table 4. Pairwise correlations between QIs were low; |w|was,0.1
for most correlations and no more than 0.35 for any pair.
A univariable regression model showed that World Bank income
level was not associated with laboratory QI score, and thus it was not
included in the multivariable model. Laboratory volume, while statis-
tically significant, showed an extremely small effect in relation to QI
(i.e. increase of 0.07 in QI for every 10 patients; P, 0.001). Relative
to Europe, each of the regions except Africa was a significant
predictor of a lower laboratory QI score (P, 0.01). However,
these predictors together explained,30% of the variance in labora-
tory QI score (R2 ¼ 0.28).
Discussion
The IAEA-sponsored INCAPS study found that while the worldwide
median laboratory radiation dose from MPI was 10.9 mSv, equivalent
to over 4 years of natural background radiation,5 this ranged over an
order of magnitude (2.2–24.4 mSv) depending on the laboratory,
and fewer than a third of laboratories achieved a median ED
≤9 mSv as recommended in professional society guidelines. More-
over, adherence to radiation safety best practices was incomplete
among the laboratories observed. Only three of the eight best prac-
tices were adopted by at least 90% of laboratories, and only 7% of la-
boratories adhered to all eight best practices. Thus, almost all
laboratories have the potential to increase the number of best prac-
tices used. Each best practice can be easily adopted, at least in some
form, with no additional resource requirements, and some may even
reduce resources required, e.g. the amount of radiopharmaceutical
used as well as staff and scanner time in the case of stress-only studies.
Of the individual best practices, performing stress-only studies
where possible and using weight-based dosing for Tc-99m studies,
were the two areas with lowest adherence worldwide and thus the
greatest potential for improvement among laboratories. Stress-only
technetium imaging has gained particular emphasis in recent profes-
sional guidelines, and can be performed with no special requirements
in terms of technology or isotopes. It entails performing stress
imaging first and then omitting the higher dose rest images in a
patient with completely normal stress images. This reduces radiation
dose by up to 80% while maintaining diagnostic utility, and has been
validated in clinical studies involving over 20 000 patients.23 We
observed stress-only imaging, to be performed in only 30% of labora-
tories worldwide, and only 13% of MPI studies, despite its having
the potential to impact ED for the majority of patients with low-
risk MPI findings. We noted a similarly low proportion of laboratories
performing weight-based dosing, i.e. adjusting administered Tc-99m
activity to reflect patient weight.
Of the eight best practices, two were not associated with lower
patient ED in the multivariable model. Only two laboratories did
not adhere to avoidance of ‘too much thallium,’ and thus our study
was not powered to reveal its effect. Avoidance of inappropriate
dosing that can lead to ‘shine through’ artefact was shown to increase
patient ED. While this serves as a best practice impacting on ED, the
expert panel included it despite a priori not expecting it be associated
with lower dose. To avoid shine through, which compromises MPI
image interpretation, guidelines recommend that activity for the
second injection be sufficiently high to minimize the impact of re-
sidual counts on images (Table 1). Accordingly, while avoidance of
shine through is an important dose-related best practice, its imple-
mentation in fact entails administration of a higher activity and
hence higher dose.
INCAPS found lower ED among patients who underwent MPI
in laboratories adhering to more of the specified best practices,
thereby providing validation of these practices. This relationship
also suggests the importance of developing, validating, and implement-
ing strategies that increase adherence to best practices. Potential
approaches include educational interventions targeting laboratory-
specific deficiencies in best practices, linking their use to reimburse-
ment and laboratory accreditation, public reporting of QIs, and the
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Table 4 Relationship between laboratory best-practice adherence and predicted patient effective dose of radiation
Best practice/factor Reduction in predicted
effective dose (mSv)
95% confidence interval Standard error P-Value
Avoid thallium stress 2.54 1.39 to 3.69 0.58 ,0.001
Avoid dual isotope 5.42 3.77 to 7.06 0.84 ,0.001
Avoid too much technetium 3.12 2.19 to 4.06 0.48 ,0.001
Avoid too much thallium 1.05 22.81 to 4.91 1.97 0.595
Perform stress-only imaging 2.28 1.57 to 2.98 0.36 ,0.001
Use camera-based dose-reduction strategies 1.23 0.58 to 1.88 0.33 ,0.001
Weight-based dosing for technetium 0.84 0.13 to 1.57 0.37 0.021
Avoid ‘shine through’ 21.03 21.66 to 20.39 0.32 0.002
Age (years) 20.004 20.009 to 0.001 0.003 0.142
Female 0.30 0.18 to 0.43 0.06 ,0.001
Weight (kg) 20.04 20.04 to 20.03 0.002 ,0.001
Intercept (predicted effective dose, mSv) 20.5 16.5 to 24.5 2.05 ,0.001
Results of the final hierarchical regression model.
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use of checklists.24 Such strategies can be realized by laboratories
working in partnership with organizations such as the IAEA, profes-
sional societies, and regulatory agencies.
We observed significant differences in both ED and QI between
countries and world regions. World regions where average patient
EDs were lowest also showed the highest rates of laboratory adher-
ence to best practices. For example, the lowest median ED (8.0 mSv)
and highest proportion of laboratories with median ED ≤9 mSv oc-
curred in Europe, which had the second highest regional best practice
adherence (mean laboratory QI 6.2) and was home to more than
three quarters of all laboratories observed worldwide with perfect
QI scores of 8. The highest median radiation dose (12.1 mSv) and
lowest proportion of laboratories with median ED ≤9 mSv (11%)
occurred in Latin America, which also had the lowest proportion
of laboratories with QI scoreof at least 6. North American laborator-
ies also performed poorly in terms of mean ED and QIs.
Regional differences in utilization of some best practices contribu-
ted in part to the marked regional differences in MPI radiation dose.
For example, the use of stress-only imaging was performed in 67% of
the limited number (12) of African laboratories and in 46% of Euro-
pean laboratories, but only in 16–23% of laboratories in the other
world regions. Camera-based dose-reduction strategies were used
in 88% of laboratories in Oceania, and 60–70% of laboratories in
other world regions, except for Latin American, where usage was
only 44%. These comprise a variety of practices (Table 1), including
the use of recent technological approaches which can maintain
image quality while reducing ED to a fraction of that with standard
protocols, but may be too costly for many laboratories. They also
include combinedproneand supine imaging, which can be performed
with virtually any standard SPECT camera, and attenuation correc-
tion; both facilitate performance of stress-only imaging. Interestingly,
the use of camera-based dose-reduction strategies was by far the
highest in Oceania, where additional reimbursement is provided
for CT-based attenuation correction. The impact of economic
factors on best-practice utilization and on ED requires further study.
As the global burden of cardiovascular disease grows and redistri-
butes to the developingworld,25 increasedutilization of cardiovascular
procedures involving ionizing radiation, such as MPI, can dramatically
influence radiation exposure to populations and hence potentially
influence cancer morbidity and mortality. The significant geographical
variation observed here in radiation doses and best practice use points
to numerous opportunities, tailored to the laboratory and population
of interest, to reduce the global burden of ionizing radiation from MPI
and its associated cancer risk. For example, although radiation doses in
Oceania were lower than the world average, utilization of stress-only
imaging and weight-based dosing was very low. Future efforts in this
population could focus on these best practices.
Our study is not without limitations. First, the extent to which
participating INCAPS laboratories are representative of all nuclear
cardiology laboratories worldwide is unknown. Since the data collec-
tion instrument was distributed through multiple channels with
overlapping constituencies, and no reliable statistics exist regarding
the number of nuclear cardiology laboratories worldwide, it was
not possible for us to identify the response rate to our request for
data. Respondents to a request for data from the IAEA may well re-
present a subset of laboratories with a better distribution of best
practice use than that of all laboratories worldwide. In some parts
of the world, for example in Russia, despite substantial efforts we
had difficulty obtaining laboratory participation, and country-level
ED and QI estimates may be more prone to sampling error when
few laboratories were surveyed. Nevertheless, we believe that
IAEA’s extensive worldwide network, and our intensive outreach
efforts, led to the broadest possible worldwide participation in
INCAPS, thus making our findings widely generalizable. Secondly,
our analysis is based on data collected over a limited timeframe
that may not be completely representative of laboratories’ practice.
Thirdly, there are rare clinical scenarios where non-adherence to
some of the best practices identified by our expert panel is war-
ranted. For example, the lifetime probability of radiation-attributable
cancer from MPI is exceedingly small in patients with low life expect-
ancy,26 and the use of higher doses maybewarranted in such patients.
Even so, we believe that the components of the QI are generally valid
and that, notwithstanding such exceptions, a laboratory paying
careful attention to radiation safety practices will invariably have a
high QI score. Nevertheless, caution should be exercised in inter-
preting a QI score in terms of predicted radiation dose, since in
calculating the QI, its components are not weighted in terms of
impact on radiation dose, and thus an identical score may have differ-
ent implications in terms of ED depending on the particular best prac-
tices used. Fourthly, our study focused by design on radiation dose
optimization, not on justification or appropriateness of MPI examina-
tions performed; avoiding inappropriate examinations is a comple-
mentary approach to minimizing population radiation burdens.27
Finally, INCAPS did not assess image quality and thus the relation-
ships between radiation best practices and radiation dose, and MPI
image quality, could not be evaluated.
While MPI conveys numerous benefits, it exposes patients to
ionizing radiation.7,10,28 In the INCAPS study of worldwide nuclear
cardiology practices, only a minority of laboratories achieved tar-
geted radiation dose levels. Adherence to radiation safety best prac-
tices varied significantly between laboratories and world regions,
however, patients undergoing procedures at laboratories adhering
to best practices received significantly lower radiation doses. This
relationship offers numerous opportunities to improve best practice
use and thereby reduce radiation exposure from MPI across the
globe.
Supplementary material
Supplementary material is available at European Heart Journal online.
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